Core Points - Jiangsu Sihuan Biological Co., Ltd. has changed its registered address and revised its Articles of Association, which were approved by the board and shareholders [1][2] - The company has completed the necessary business registration changes and obtained a new business license [1] - The new registered information includes the company name, unified social credit code, type, legal representative, registered capital, establishment date, and new address [1] Company Information - Company Name: Jiangsu Sihuan Biological Co., Ltd. [1] - Unified Social Credit Code: 913202001381477183 [1] - Type: Joint-stock company (listed) [1] - Legal Representative: Qiu Weibing [1] - Registered Capital: 1,029.556222 million RMB [1] - Establishment Date: May 18, 1992 [1] - New Address: 41st Floor, No. 2 Binhai East Road, Jiangyin City [1] Business Scope - The company manufactures large-volume injectables, small-volume injectables (including anti-tumor drugs), tablets (including anti-tumor drugs), hard capsules, syrups, oral solutions, alcohol preparations, raw materials, and traditional Chinese medicine extracts [1] - It also engages in the manufacturing of pharmaceutical intermediates (excluding chemical hazardous products), medical information consulting, technology transfer services, and various manufacturing and sales activities [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开 了第十届董事会第十三次会议，审议通过了《关于变更注册地址并修订 <公司章> 程>的议案》（公告编号：临-2025-38 号），上述议案已经 2025 年第三次临时 股东会审议通过（公告编号：临-2025-46 号）。 近日，公司已完成了相关工商变更登记和章程备案手续，并取得了新的《营 业执照》，公司变更后的注册信息如下： 公司名称：江苏四环生物股份有限公司 统一社会信用代码：913202001381477183 股 票 代 码 ： 000518 股 票 简 称 ： *ST 四 环 公 告 编 号 ： 临 -2025-49 号 江苏四环生物股份有限公司 关于完成工商变更登记备案并换发营业执照 暨变更办公地址的公告 江苏四环生物股份有限公司 类型：股份有限公司（上市） 法定代表人：邱为碧 注册资本：102,955.6222 万人民币 成立日期：1992 年 5 月 18 日 住所：江阴市滨江东路 2 号 41 楼 05、06 座 经营范 ...

股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * S T 四 环 公 告 编 号 ： 临 - 2025 - 4 9 号 江苏四环生物股份有限公司 关于完成工商变更登记备案并换发营业执照 统一社会信用代码：913202001381477183 类型：股份有限公司（上市） 法定代表人：邱为碧 注册资本：102,955.6222 万人民币 成立日期：1992 年 5 月 18 日 住所：江阴市滨江东路 2 号 41 楼 05、06 座 暨变更办公地址的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江苏四环生物股份有限公司（以下简称"公司"）于 2025 年 6 月 4 日召开 了第十届董事会第十三次会议，审议通过了《关于变更注册地址并修订<公司章 程>的议案》（公告编号：临-2025-38 号），上述议案已经 2025 年第三次临时 股东会审议通过（公告编号：临-2025-46 号）。 近日，公司已完成了相关工商变更登记和章程备案手续，并取得了新的《营 业执照》，公司变更后的注册信息如下： 公司名称：江苏四环生物股份有限公司 股 票 代 码 ...

Core Viewpoint - Jiangsu Sihuan Bioengineering Co., Ltd. (referred to as "Sihuan Bio" or "*ST Sihuan") expects to increase revenue without profit in the first half of 2025, projecting revenue of approximately 180 million to 190 million yuan, a year-on-year increase of 70.12% to 79.57%, while net profit attributable to shareholders is expected to be a loss of 9 million to 13 million yuan, widening from a loss of 11.0581 million yuan in the same period last year [1][2]. Group 1: Financial Performance - Sihuan Bio's revenue is projected to grow significantly due to bulk sales of seedlings by its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., despite a slight decline in revenue from its main subsidiary, Beijing Sihuan Bio-Pharmaceutical Co., Ltd. [2] - The company has reported continuous losses for four consecutive years, with revenues of 351 million yuan, 270 million yuan, 235 million yuan, and 204 million yuan from 2021 to 2024, and corresponding losses of 34.79 million yuan, 48.79 million yuan, 75.27 million yuan, and 110 million yuan [6][8]. Group 2: Legal and Regulatory Issues - Sihuan Bio is facing ongoing financial burdens due to securities false statement liability disputes, with 188 investors filing lawsuits against the company, totaling 41.2075 million yuan in claims [3]. - The company has been penalized by the China Securities Regulatory Commission (CSRC) for false disclosures regarding its actual controller, leading to administrative penalties and market bans for the former actual controller, Lu Keping [4][5]. Group 3: Market Challenges - The company is experiencing significant sales pressure due to intensified competition and price reductions in the pharmaceutical industry, particularly in the context of centralized drug procurement [7][8]. - Despite an increase in research and development (R&D) personnel and investment, the company’s core pharmaceutical business has not shown substantial improvement, relying instead on non-core business revenue for short-term gains [8].

Core Viewpoint - The company, Jiangsu Sihuan Biological Co., Ltd., anticipates a significant increase in revenue for the first half of 2025, despite reporting a net loss attributed to various operational challenges [1][2]. Financial Performance Summary - Expected operating revenue for the period is projected to be approximately 105.81 million yuan, representing a year-on-year growth of 70.12% to 79.57% [1]. - The net loss attributable to shareholders is estimated to be between 9 million to 13 million yuan, compared to a loss of 11.06 million yuan in the same period last year, indicating a decrease of 17.56% to 18.61% [1]. - The net loss after deducting non-recurring gains and losses is expected to be between 10 million to 14 million yuan, a decline of 42.75% to 1.96% compared to a loss of 9.81 million yuan last year [1]. - Basic earnings per share are projected to be between -0.0126 yuan and -0.0087 yuan, compared to -0.0107 yuan per share in the previous year [1]. Reasons for Performance Changes - The primary reason for the company's losses is a slight decline in revenue from its subsidiary, Beijing Sihuan Biological Pharmaceutical Co., Ltd., along with increased management expenses due to legal fees related to a securities fraud case [2]. - Conversely, the increase in operating revenue is attributed to a strategic cooperation agreement between its wholly-owned subsidiary, Jiangsu Chenwei Ecological Park Technology Co., Ltd., and Jiangyin Xinganfa Trading Co., Ltd., leading to a substantial rise in sales of seedlings [2]. Other Relevant Information - The performance forecast is based on preliminary estimates from the company's finance department, with final figures to be confirmed in the official half-year report for 2025 [2].

Core Viewpoint - *ST SiHuan (000518) expects a significant increase in revenue for the first half of 2025, while still projecting a net loss for the same period [1] Revenue Forecast - The company anticipates revenue between 180 million to 190 million yuan for the period from January 1, 2025, to June 30, 2025, representing a year-on-year growth of 70.12% to 79.57% [1] Profitability Outlook - The expected net loss attributable to shareholders is projected to be between -13 million to -9 million yuan, reflecting a year-on-year change of -17.56% to 18.61% [1] - The net loss after excluding non-recurring gains and losses is forecasted to be between -14 million to -10 million yuan, indicating a year-on-year decline of 42.75% to -1.96% [1] Earnings Per Share - The basic earnings per share is estimated to be between -0.0126 yuan to -0.0087 yuan [1]

[Jiangsu Sihuan Bioengineering Co., Ltd. 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E6%B1%9F%E8%8B%8F%E5%9B%9B%E7%8E%AF%E7%94%9F%E7%89%A9%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8%202025%20%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company forecasts H1 2025 operating revenue between **180 million and 190 million yuan**, a **70.12% to 79.57%** increase, but expects a net loss attributable to shareholders ranging from **9 million to 13 million yuan** Performance Forecast for H1 2025 | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Period | | :--- | :--- | :--- | | **Operating Revenue** | 180 million yuan to 190 million yuan | 105.8084 million yuan | | | Year-on-year growth: 70.12% to 79.57% | | | **Net Profit Attributable to Shareholders of Listed Company** | Loss: -13 million yuan to -9 million yuan | -11.0581 million yuan | | | Year-on-year change: -17.56% to 18.61% | | | **Net Profit After Deducting Non-Recurring Gains and Losses** | Loss: -14 million yuan to -10 million yuan | -9.8074 million yuan | | | Year-on-year decrease: -42.75% to -1.96% | | | **Basic Earnings Per Share** | -0.0126 yuan/share to -0.0087 yuan/share | -0.0107 yuan/share | [Pre-Audit Status of Performance Forecast](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A%E9%A2%84%E5%AE%A1%E8%AE%A1%E6%83%85%E5%86%B5) This performance forecast has not been audited by a certified public accountant, and its accuracy awaits final audit confirmation - This performance forecast has not been audited by a certified public accountant[2](index=2&type=chunk) [Analysis of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0) During the reporting period, the company experienced revenue growth without profit increase, primarily due to subsidiary's nursery stock sales and increased losses from the core pharmaceutical subsidiary, compounded by rising management fees from litigation expenses - Significant growth in operating revenue is primarily due to a strategic cooperation agreement between wholly-owned subsidiary Jiangsu Chenwei Ecological Park Technology Co., Ltd. and Jiangyin Xingangfa Trading Co., Ltd. for bulk sales of nursery stock[3](index=3&type=chunk) - The main reasons for the performance loss are a decrease in main business revenue and increased losses from the controlling subsidiary Beijing Sihuan Bio-Pharmaceutical Co., Ltd., and increased management expenses and losses for the parent company due to legal fees for securities false representation lawsuits[3](index=3&type=chunk) [Other Relevant Information and Risk Warning](index=1&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states that this performance forecast is a preliminary estimate, with final accurate financial data subject to the 2025 semi-annual report, advising investors of potential investment risks - This performance forecast data is a preliminary estimate by the company's finance department, with specific data subject to the company's 2025 semi-annual report, reminding investors to be aware of investment risks[4](index=4&type=chunk)[5](index=5&type=chunk)

2020年4月，江苏四环生物股份有限公司（以下简称"公司"）因虚假陈述 被中国证监会作出行政处罚及市场禁入（详见公司临-2020-22号公告）。 股 票 代 码 ： 0 0 0 5 1 8 股 票 简 称 ： * S T 四 环 公 告 编 号 ： 临 - 2025 - 4 7 号 江苏四环生物股份有限公司 关于投资者索赔事项的进展公告 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，公 告不存在虚假记载、误导性陈述或者重大遗漏。 一、投资者索赔案件基本情况 公司将积极跟进相关诉讼进展，进行相应的会计处理并按规定及时履行信息 披露义务，敬请各位投资者理性投资，注意投资风险。 特此公告。 江苏四环生物股份有限公司 2025年7月8日 1 截至本公告日,公司共收到了南京市中级人民法院送达的188名投资者的诉 讼材料，原告以证券虚假陈述责任纠纷为由对公司提起民事诉讼，累计金额为 4,120.75万元。 上述案件中，已有154名投资者与公司达成了诉前或诉中调解，公司累计支 付调解款918.70万元；另有7名投资者因诉讼时效，一审判决公司胜诉，目前原 告投资者已上诉。 二、其他尚未披露的诉讼仲裁事项 截 ...

Core Viewpoint - The article discusses the recent administrative penalties imposed on Lu Keping, the former actual controller of Sihuan Bio, highlighting the company's ongoing struggles and the impact of leadership changes on its financial performance [1][4][5]. Group 1: Administrative Penalties and Legal Issues - Lu Keping was fined 6 million yuan for failing to disclose significant legal issues affecting Sihuan Bio and Jiangsu Sunshine, leading to major omissions in their annual reports from 2020 to 2023 [1][4]. - Lu Keping has faced multiple criminal charges, including insider trading, resulting in a three-year prison sentence with a four-year suspension [4][6]. - The Securities Regulatory Commission (SRC) has previously issued warnings regarding Lu Keping's actions, which included illegal stock trading and misleading disclosures about the company's actual controller [3][4]. Group 2: Company Performance and Financial Struggles - Sihuan Bio has experienced continuous losses for four years, with revenue declining from 351 million yuan in 2021 to 204 million yuan in 2024, while losses increased from 34.79 million yuan to 110 million yuan during the same period [7][8]. - The company's main business has shifted over the years, currently focusing on biopharmaceuticals, which accounted for 97.34% of its revenue in 2024 [7]. - Factors contributing to the financial decline include increased costs from legal disputes, competitive pressures in the pharmaceutical market, and asset impairment losses due to declining prices in the landscaping business [8]. Group 3: Changes in Ownership and Future Outlook - In early 2024, Sihuan Bio transitioned to new ownership under Bihui Investment after a public auction of shares previously controlled by Lu Keping [6][5]. - The company is implementing measures to improve its financial situation, including optimizing management and controlling expenses, in response to its current operational challenges [8].

江苏四环生物股份有限公司 董事会议事规则 第一章 总则 第一条 为明确江苏四环生物股份有限公司（以下简称"公司"）董事会的 职责权限，规范公司董事会的议事方式和决策程序，促使公司董事和董事会有效 地履行其职责，提高公司董事会规范运作和科学决策水平，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《上市公司治理准则》和《深圳证券交易所股票上市规则》 （以下简称"《上市规则》"）及《江苏四环生物股份有限公司章程》（以下简 称"《公司章程》"）等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会，董事会对股东会负责。 第三条 公司董事会由 5 名董事组成，其中独立董事 2 名，且至少包括一名 会计专业人士。 第四条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或减少注册资本、发行债券或其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立和解散及变更公 司形式的 ...